ArticleHistopathology2026
Unveiling the molecular profile of adenosquamous gallbladder carcinoma: characterization of a Caucasian cohort.
Article in Histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
aimsGallbladder carcinoma (GBC) is a rare and highly aggressive malignancy associated with poor clinical outcomes. While most GBCs are adenocarcinomas, only a small subset shows squamous differentiation. Tumours containing more than 25% squamous component are classified as gallbladder adenosquamous carcinomas (GBASC), a rare histological subtype characterized by a significantly worse prognosis than conventional adenocarcinomas. Due to their rarity, the molecular landscape and biological basis underlying the aggressive behaviour of GBASCs remain poorly understood. METHODS AND
resultsIn this study, 25 retrospectively collected GBASC cases were comprehensively characterized at both immunohistochemical and molecular levels. Predictive biomarkers including programmed death-ligand 1 (PD-L1), mismatch repair proteins (MMR), human epidermal growth factor receptor 2 (HER2) and claudin 18.2 (CLDN18.2) were evaluated. Nearly all tumours (96%) showed PD-L1 positivity with a combined positive score (CPS) greater than 1. CLDN18.2 expression was identified in 28% of cases, although its confinement to the glandular component may limit its therapeutic applicability. All tumours were mismatch repair proficient (MMRp), and none demonstrated HER2 overexpression, in contrast to a subset of gallbladder adenocarcinomas. Molecular profiling revealed recurrent alterations in TP53 (64%), KRAS (16%) and CDKN2A (20%), partially overlapping with the genomic profile of gallbladder adenocarcinomas. However, GBASCs showed a significant enrichment of alterations involving the PI3K pathway, particularly PIK3CA (44%) and PTEN (24%) mutations, representing their most distinctive molecular feature.
conclusionsOverall, these findings support the recognition of GBASC as a distinct molecular entity potentially requiring dedicated therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.